Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDO-JAK: Dose Reduction of JAK Inhibitors
NCT07160231Phase 4Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of baricitinib, filgotinib, tofacitinib, upadacitinib in rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), sponsored by Sint Maartenskliniek. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT07160231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160231.